Science
About INTASYL™
INTASYL is a patented precision delivery technology which delivers uniquely designed gene silencing compounds to any gene target in the human genome.
It effectively targets messenger RNA to suppress specific proteins, genetically encoded in the DNA, that can interfere with the body’s immune cells in killing cancer cells, resulting in the reduction of specific protein targets. It has been safely tested in human trials in >170 patients.
The INTASYL technology facilitates the creation of unique, chemically modified siRNA compounds (INTASYL compounds), which can be delivered to a broad range of cell types and tissues without the need for enhancements. INTASYL’s innovative approach features a simplified chemical composition, effectively reducing toxicity and enhancing tolerability and efficacy. This technology is adaptable to both intra-tumoral and adoptive cell therapy (ACT) applications, ensuring a versatile and potent therapeutic platform for gene silencing.
How INTASYL™ Works
Pipeline
Program
Discovery
Preclinical Proof
of Concept
IND Enabling
Studies
IND Clearance
Clinical Phase
PH-762 IT
Stage I-II-IV cSCC
Stage IV Melanoma
Stage IV Merkel Cell
Read More
PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells.
Target(s) & Indication: PD-1
cSCC, Advanced Melanoma, Merkel Cell
PH-762 ACT+
Double Positive TILS
Melanoma
Other Solid Tumors
Read More
PH-762 is an INTASYL compound that reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells.
Target(s) & Indication: PD-1
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma, and other solid tumors
PH-894
BRD4 protein suppression
Stage IV Melanoma,
HNSCC, HCC
Read More
PH-894 is an INTASYL compound that silences BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby effecting the immune system as well as the tumor.
Target(s) & Indication: BRD-4
Advanced Melanoma, Merkel Cell, HCC, TNBC
PH231
Tyrosinase Inhibitor.
Skin Lightner
Read More
Key Clinical Initiatives & Programs
PH-762
- The Phase 1b trial is a non-comparative study of neoadjuvant monotherapy using PH-762 in adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. The trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose or dose range for continued study of PH-762.
- Learn more
- Learn more about the clinical trial.
PH-894
- PH-894 is designed to silence the BRD4 protein. Overexpression of BRD4 is often associated with cancer progression, invasion, and metastasis. What sets PH-894’s approach to silencing BRD4 apart is its dual activity in suppressing BRD4 in both T cells and in tumor cells: PH-894’s suppression of BRD4 in T cells results in T cell activation; additionally, suppression of BRD4 in tumor cells results in tumors becoming more sensitive to T-cell killing.
- Learn more
Scientific Resources
Investors
About us
Contact us
